Natco Pharma Ltd

General

Total Cases69

Active Cases14

Patents49

CourtsD. Delaware D. New Jersey S.D. New York

TypeOperating Company

Elite Ratings

--

natcopharma.co.in

Ratings

Experience

Grade

Trend

DCT

L3

E

PTAB

L3

D

CAFC

L2

B

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/17/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Summons Issued as to Natco Pharma Limited, Natco Pharma USA LLC, Natco Pharma, Inc. (Attachments: # [1] Summons - Natco Ltd., # [2] Summons - Natco USA.)(mws) (Entered: 09/17/2024)
09/17/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mws) (Entered: 09/17/2024)
09/17/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka America, Inc., Corporate Parent Otsuka Pharmaceutical Co., Ltd., Other Affiliate Otsuka Holdings Co., Ltd. for Astex Therapeutics, Ltd. filed by Astex Therapeutics, Ltd. (mws) (Entered: 09/17/2024)
09/16/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/30/2024. Date of Expiration of Patent: 11/09/2031.Thirty Month Stay Deadline: 1/30/2027. (mws) (Entered: 09/16/2024)
09/16/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,193,732; 9,868,739. (mws) (Entered: 09/16/2024)
09/16/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mws) (Entered: 09/16/2024)
09/16/24	Novartis Pharmaceuticals Corp v. Natco Pharma Ltd 1:24-CV-01033 ( D. DE )	COMPLAINT for ANDA / PATENT INFRINGEMENT filed against Natco Pharma Limited, Natco Pharma USA LLC, and Natco Pharma, Inc. (Filing fee $ 405, receipt number ADEDC-4498137.) - filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics, Ltd. (Attachments: # [1] Exhibit A-B, # [2] Civil Cover Sheet)(mws) (Entered: 09/16/2024)
09/13/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024) CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024)
09/12/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	ORDER granting [138] view138 Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement. The parties may file their Joint Disputed Claim Terms Chart and PrehearingStatement by September 13, 2024. Signed by Judge Robert J. Colville on 9/12/24. Text-only entry; no PDF document will issue. This text-only entry constitutes the Order of the Court or Notice on the matter. (cjo) (Entered: 09/12/2024) ORDER granting [138] view138 Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement. The parties may file their Joint Disputed Claim Terms Chart and PrehearingStatement by September 13, 2024. Signed by Judge Robert J. Colville on 9/12/24. Text-only entry; no PDF document will issue. This text-only entry constitutes the Order of the Court or Notice on the matter. (cjo) (Entered: 09/12/2024)
09/11/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement by GLAND PHARMA, LTD., MYLAN PHARMACEUTICALS, INC., MYLAN TEORANTA, MYLAN, INC., NATCO PHARMA, LTD., VIATRIS, INC.. (Attachments: # 1 Proposed Order Proposed Order) (Pietragallo, William) (Entered: 09/11/2024)